Skip to main content

Table 1 Clinical characteristics of the patients with benign biliary tract disease (control) and cholangiocarcinoma

From: Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy

 

Control

(n = 36)

Cholangiocarcinoma

(n = 44)

p value

Age (Yr)

54 ± 14.5

59 ± 12.9

0.130

Sex (Male:Female)

15:16

26:18

0.248#

Total bilirubin (mg/dL)

4.2 ± 5.53

14.6 ± 11.34

<0.001*

Direct bilirubin (mg/dL)

2.6 ± 3.75

10.3 ± 8.47

<0.001*

Albumin (g/dL)

3.8 ± 0.61

3.1 ± 0.68

0.050

Globulin (g/dL)

3.6 ± 0.73

4.1 ± 0.93

0.253

AST (U/L)

65.4 ± 53.80

183.9 ± 378.82

0.012*

ALT (U/L)

75.0 ± 77.72

101.4 ± 14.49

0.615

ALP (IU/L)

318.6 ± 349.65

551.8 ± 526.04

0.001*

  1. Quantitative variables are presented as the means ± standard deviation. #; Pearson Chi-square was used to compare between two groups, *; the level of serum total bilirubin, direct bilirubin, AST and ALP were significantly higher in cholangiocarcinoma patients than in controls (Mann-Whitney U test; p < 0.05).
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us